Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present NeoGenomics, Inc. (NASDAQ: NEO).

Full DD Report for NEO

You must become a subscriber to view this report.


Recent News from (NASDAQ: NEO)

NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier
FT. MYERS, Fla., Sept. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has been awarded a group purchasing agreement for clinical reference laboratory testing services with Premier. Effect...
Source: GlobeNewswire
Date: September, 12 2018 08:13
Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball Corporation (NYSE:BLL), Aethlon Medical, Inc. (NASDAQ:AEMD), NeoGeno...
Source: GlobeNewswire
Date: August, 27 2018 08:00
Premarket analyst action - healthcare
NeoGenomics (NASDAQ: NEO ) initiated with Outperform rating and $18 (40% upside) price target at Leerink Partners. More news on: NeoGenomics Inc., Audentes Therapeutics, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 21 2018 08:18
Premarket Losers as of 9:05 am (8/10/2018)
GEMP   -65%  on terminating Phase 2a clinical trial assessing gemcabene in pediatric patients with NAFLD. More news on: Gemphire Therapeutics, Corcept Therapeutics Incorporated, Avalara, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 09:15
NeoGenomics announces pricing of common stock
NeoGenomics (NASDAQ: NEO ) priced underwritten public offering of 9.8M common stock at $12.75/share for gross proceeds of ~$125M More news on: NeoGenomics Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 10 2018 05:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1413.5613.9914.1413.39471,343
2017-02-038.148.128.157.9927,417
2017-02-028.148.058.197.90273,913
2017-02-018.108.148.2498.04282,735
2017-01-318.058.068.107.71571,266

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12285,4751,562,37518.2719Cover
2018-12-11141,733437,13632.4231Cover
2018-12-1077,692343,63122.6091Cover
2018-12-0781,422255,73331.8387Cover
2018-12-06134,772432,84531.1363Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NEO.


About NeoGenomics, Inc. (NASDAQ: NEO)

Logo for NeoGenomics, Inc. (NASDAQ: NEO)

NeoGenomics Laboratories is a specialized genetics laboratory providing the latest diagnostic testing technologies to the pathology and oncology Communities. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories.

 

Contact Information

 

 

Current Management

  • Douglas M. VanOort / CEO
  • George Cardoza / CFO
  • Steven C. Jones / EVP, Fin.
  • Grant Carlson / VP, Business Development
  • Robert Horel / VP, Sales amp Mktg.
  • Jerome J. Dvonch / Director, Fin.
  • Edwin F. Weidig III / Principal Acct. Officer, Director, Fin.
  • Raymond R. Hipp /

Current Share Structure

  • Market Cap: $904,899,737 - 05/18/2018
  • Issue and Outstanding: 80,507,094 - 03/05/2018

 


Recent Filings from (NASDAQ: NEO)

Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: August, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 06 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: August, 06 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: August, 03 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: August, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 24 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: July, 05 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: June, 26 2018

 

 


Daily Technical Chart for (NASDAQ: NEO)

Daily Technical Chart for (NASDAQ: NEO)


Stay tuned for daily updates and more on (NASDAQ: NEO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NEO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NEO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NEO and does not buy, sell, or trade any shares of NEO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/